Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Conference Call October 17, 2023 8:30 AM ET
Company Participants
Jessica Moore - Vice President, Investor Relations
Joe Wolk - Executive Vice President, Chief Financial Officer
John Reed - Executive Vice President, Pharmaceuticals, R&D
Joaquin Duato - Chairman and Chief Executive Officer
Erik Haas - Vice President, Litigation
Ahmet Tezel - Innovative Medicine and MedTech R&D
Conference Call Participants
David Risinger - Leerink Partners
Matt Miksic - Barclays
Chris Shibutani - Goldman Sachs
Geoff Meacham - Bank of America
Josh Jennings - TD Cowen
Chris Schott - JPMorgan
Larry Biegelsen - Wells Fargo
Terence Flynn - Morgan Stanley
Joanne Wuensch - Citibank
Vamil Divan - Guggenheim Securities
Danielle Antalffy - UBS
Louise Chen - Cantor Fitzgerald
Operator
Good morning, and welcome to Johnson & Johnson's Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions]
I would now like to turn the conference call over to Johnson & Johnson. You may begin.
Jessica Moore
Good morning. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of the 2023 third quarter business results and full-year financial outlook.
A few logistics before we get into the details. As a reminder, you can find additional materials, including today's presentation and associated schedules, on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events using the information available as of the date of this recording and are subject to certain risk and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2022 Form 10-K, which is available at investor.jnj.com and on the SECs website.
Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.
Moving to today's agenda. I will start by reviewing the third quarter sales and P&L results for the corporation and highlights related to our two businesses. Joe Wolk, our CFO will then provide additional business and financial commentary before sharing an overview of our cash position, capital allocation priorities, and updated guidance for 2023. The remaining time will be available for your questions.